Clinical Trial · NCT05073653

A Study of 68Ga-GRP PET/CT for Imaging in Low and Intermediate Risk Prostate Cancer

Overview

Patients with primary low and intermediate risk prostate cancer (PCa) for whom radical prostatectomy are indicated, will be invited to participate to the present study. The aim of this study is to investigate the clinical value of 68Ga-GRP positron emission tomography / computed tomography (PET/CT) compared to 68Ga-PSMA PET/CT in patients with low and intermediate risk PCa.

Sponsor

Xiangya Hospital of Central South University

Phase

N/A

Contacts

Shuo Hu, PhD, MD (CONTACT)

hushuo_xy@163.com

+86 15874210819

Shuo Hu, PhD, MD (STUDY_DIRECTOR)

Yongxiang Tang, PhD, MD (CONTACT)

xyyf0401@qq.com

+86 13549654360

ClinicalTrials.gov

NCT05073653

Drug / Compound

PSMA

Isotope(s):

Target(s):

PSMA

Ligand Class: Small Molecules

Chelator: HBED-CC

GRP

Isotope(s):

Target(s):

GRPR

Ligand Class: Peptides

Chelator: DOTA

Eligibility

Inclusion

Candidate for radical prostatectomy after discussion in multidisciplinary committee;
patients divided in :
Patients with low risk prostate cancer (Gleason score ≤ 6 and cT1-T2a and Prostate Specific Antigen (PSA) value \< 10 ng/mL);
Patients with high risk prostate cancer (Gleason \> 7 or cT2c or PSA value \> 20 ng/mL);
Patients with intermediate risk prostate cancer (Gleason score 7 or cT2b or PSA value 10-20 ng/mL);

Exclusion

Patient not candidate for radical prostatectomy and/or unable to benefit from surgery;
Any kind of previous treatment for prostate cancer (hormonal treatment, EBRT, brachytherapy, cryotherapy, etc…);
Patient under legal protection or unable to express its own consent;
Patient within exclusion period from another clinical trial;
Claustrophobia (unable to accept PET/CT scanning).